drugset / Trial / NCT05438758
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
Timeline
- Start
- 2023-01-15
- Primary completion
- 2024-02-01
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esketamine | Other / unclassified | 56 mg | Intranasal |
| Subject | Esketamine | Other / unclassified | 84 mg | Intranasal |